Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00883415 · ClinicalTrials.gov registry record

Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease

A clinical trial, sponsored by University of Maryland, Baltimore.

Completed
Registry status
20
Enrollment target

NCT00883415 is a clinical trial that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00883415 has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
20 participants
Enrollment target

Study Summary

This study examines patients with chronic kidney disease-related anemia and measures changes in the metabolism of the heart using FDG/PET scanning, before and 6 months after their health-care provider has initiated anemia management therapy with the FDA-approved drug darbepoetin alfa (Aranesp), which is approved for chronic kidney disease-related anemia. The investigators hypothesize that the heart has abnormal metabolism with the anemia of chronic kidney disease but this improves after correction of this anemia with darbepoetin alfa.

Interventions

  • DRUG Darbepoetin alfa

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2008-05
Est. Completion 2012-11

Sponsor

University of Maryland, Baltimore

560 total trials

What the Registry Record Tells You About NCT00883415

The ClinicalTrials.gov registry entry for NCT00883415 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Darbepoetin alfa is the first listed.

NCT00883415 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00883415 about?

NCT00883415 is a clinical study titled "Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease". This study examines patients with chronic kidney disease-related anemia and measures changes in the metabolism of the heart using FDG/PET scanning, before and 6 months after their health-care provider has initiated anemia management therapy with the FDA-approved drug darbepoetin alfa (Aranesp), whic...

What is the current status of trial NCT00883415?

This trial is currently completed. The enrollment target is 20 participants. The study started on 2008-05. Estimated completion is 2012-11.

What interventions are being tested in trial NCT00883415?

The interventions under investigation include: Darbepoetin alfa (DRUG).

Who is sponsoring clinical trial NCT00883415?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.